Antibacterial Susceptibility of Clinical Isolates of Klebsiella pneumoniae in Nigeria to Carbapenems

Elijah Kolawole Oladipo; Elukunbi Hilda Awoyelu; Idowu Jesulayomi Adeosun; Abiodun A Ayandele

doi:10.24996/ijs.2021.62.2.5

Authors

Elijah Kolawole Oladipo Department of Microbiology, Laboratory of Molecular Biology, Bioinformatics and Immunology, Adeleke University, P.M.B 250, Ede, Osun State, Nigeria.
Elukunbi Hilda Awoyelu Department of Pure and Applied Biology (Microbiology/Virology Unit), Ladoke Akintola University, P.M.B 4000, Ogbomoso, Nigeria
Idowu Jesulayomi Adeosun Department of Microbiology, Laboratory of Molecular Biology, Bioinformatics and Immunology, Adeleke University, P.M.B 250, Ede, Osun State, Nigeria
Abiodun A Ayandele Department of Pure and Applied Biology (Microbiology/Virology Unit), Ladoke Akintola University, P.M.B 4000, Ogbomoso, Nigeria

DOI:

https://doi.org/10.24996/ijs.2021.62.2.5

Keywords:

Antibiotic resistance, Aminoglycosides, Carbapenems, Clinical isolates, Klebsiella pneumoniae

Abstract

The emergent bacterial resistance to antibiotics, most especially Carbapenems, has become a common phenomenon. The aim of the recent study was the observation and evaluation of the antibacterial susceptibility of Klebsiella pneumoniae in clinical specimens to different Carbapenems. One hundred isolates of K. pneumoniae isolated from different clinical sites, such as leg, caesarean section (CS), head, buttock, breast, thigh, and arm were tested. Using disc diffusion method, the isolates were tested for susceptibility to different antibiotics including Tobramycin, Ciprofloxacin, Aztreonam, Colistin sulphate, Ceftriaxone, Cefepime, Cefoxitin, Ceftazidime, Ertapenem, Meropenem, and Imipenem. The results were interpreted according to the Clinical and Laboratory Standard Institute disk diffusion standard. All K. pneumoniae isolates were highly susceptible to all classes of Carbapenems: Imipenem (99%), Meropenem (96%) and Ertapenem (91%). However, they were highly resistant to Ciprofloxacin (97%), Ceftriaxone (91%) and Tobramycin (73%). Despite the recent emergence of multi-drug resistant bacteria to Carbapenems, this study showed that Carbapenems could still be used in treating different infections caused by multi-drug resistant K. pneumoniae.